All In Biotech

Drug Trial Radar · NCT03657030

Study of CVN424 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN424 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Sep 18, 2018

Primary completion

Mar 1, 2019

Study completion May 30, 2019

Sponsor

Lead sponsor
Cerevance Beta, Inc.Industry
Sponsor type
Industry
First posted
Sep 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.

Conditions

  • Healthy

Interventions

  • CVN424Drug

    SAD / MAD

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of adverse eventsTime frame: Baseline through 14 days post-dose
  2. Evaluation of HematologyTime frame: Baseline through 14 days post-dose
  3. Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
  4. Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
  5. Evaluation of BMITime frame: Baseline through 14 days post-dose
  6. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  7. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
  8. Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
  9. Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
  10. Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
  11. Evaluation of HematologyTime frame: Baseline through 14 days post-dose
  12. Evaluation of HematologyTime frame: Baseline through 14 days post-dose
  13. Evaluation of HematologyTime frame: Baseline through 14 days post-dose
  14. Evaluation of HematologyTime frame: Baseline through 14 days post-dose
  15. Evaluation of HematologyTime frame: Baseline through 14 days post-dose
  16. Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
  17. Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
  18. Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
  19. Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
  20. Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
  21. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  22. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  23. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  24. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  25. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  26. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  27. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  28. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  29. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  30. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  31. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  32. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  33. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  34. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  35. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  36. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  37. Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
  38. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
  39. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
  40. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
  41. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
  42. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
  43. Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Development, LP

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.